The Test That Could Catch Pancreatic Cancer Before It's Deadly

Cancer Doesn't Stop at 5 PM: Rebuilding Oncology Around the Patient

Cancer care has made extraordinary clinical progress, but too many patients still fall through the cracks once they leave the clinic. In this episode of Boombostic Health, Bradley Bostic sits down with Dr. Justin Bekelman, oncologist, co-founder, and CEO of Daymark Health, to discuss how value-based oncology can create a better care model for patients, providers, and health plans. After more than two decades at Penn Medicine, Dr. Bekelman left to build Daymark Health, a company that supports patients receiving active cancer treatment through in-home and virtual care. Daymark partners with health plans and works alongside each patient's oncology team to address clinical, behavioral, and social needs when and where they arise. The conversation explores why fee-for-service often fails to support the full cancer journey, why oncology is especially suited for value-based care, and why better care requires more than coordination. It requires the ability to act. As Dr. Bekelman explains, "Cancer doesn't stop at five o'clock." Timestamps 00:00 [https://www.youtube.com/watch?v=ccNxEOeqPPI] Welcome and personal connection to cancer prevention 03:01 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=181s] Dr. Bekelman's background and why patients still fall through the cracks 05:30 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=330s] What value-based care means in oncology 07:28 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=448s] Why supportive cancer care is under-reimbursed in fee-for-service 09:17 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=557s] How Daymark Health partners with health plans 10:32 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=632s] Supporting patients at home, virtually, and at no additional cost 12:44 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=764s] Episodic capitation, shared savings, and oncology economics 15:18 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=918s] Why cancer care is well suited for value-based models 17:24 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=1044s] Daymark as the "connective tissue" around the oncologist 20:34 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=1234s] Why coordination alone is not enough 23:01 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=1381s] Daymark's work with Blue Cross Blue Shield of Rhode Island 24:08 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=1448s] Steven's story and why cancer does not stop at 5 PM 27:37 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=1657s] Patient experience, home visits, and measurable results 30:19 [https://www.youtube.com/watch?v=ccNxEOeqPPI&t=1819s] Why this model could become the standard for cancer care In this episode: * Why cancer patients need support beyond the clinic * How value-based care is being applied to oncology * Why Daymark works through health plan partnerships * The difference between care coordination and clinical action * How in-home care can help prevent avoidable complications * Why behavioral health and social support matter in cancer treatment * How better patient support can reduce total cost of care * Why oncology may be one of the next major frontiers for value-based care

Diagnostics at the Center: Turning Real-World Data Into Better Care

Diagnostics are no longer just about confirming what is wrong. They are becoming one of the most powerful tools for predicting what comes next. In this episode of Boombostic Health, Bradley Bostic leads a timely conversation with healthcare and diagnostics leaders on how real-world patient data, genomics, AI, and embedded research models are changing the way healthcare systems identify risk, close care gaps, and deliver more personalized care. The discussion moves beyond the promise of innovation and into the practical realities of adoption. How do we turn routine care into continuous learning? How do we prove the value of advanced diagnostics to payers? How do we expand access without creating new forms of bias? And how do we help patients and providers trust the data, the science, and the recommendations that follow? From home-based testing and consumer-driven care to reimbursement, incidental findings, data diversity, and health economics, this episode explores what it will take to move diagnostics from the edge of healthcare innovation into the center of everyday clinical decision-making. What You'll Learn * How diagnostics are shifting from episodic testing to continuous healthcare intelligence * Why real-world data is essential to predicting outcomes and improving care pathways * How genomics and AI can support more personalized, proactive care * What it takes to build the business case for diagnostic innovation * Why reimbursement models must evolve to keep pace with scientific progress * How embedded research can make routine care more evidence-driven * Why patient trust, education, and transparency are critical to adoption * How data diversity can help reduce bias and improve care for underserved populations Why This Conversation Matters Healthcare does not have a data shortage. It has an actionability problem. The future of diagnostics will depend on the ability to connect data to decisions, research to routine care, and innovation to measurable impact. This conversation makes the case for diagnostics as a strategic foundation for better care, smarter economics, and more equitable outcomes. Key Moments 00:00 — Why diagnostics are becoming central to healthcare innovation 02:38 — Embedding research into routine care 04:17 — Using data to predict health outcomes 06:10 — Making the case for payer coverage and cost savings 09:58 — Bringing diagnostic models into clinical workflows 11:14 — The rise of home-based and consumer-driven testing 14:23 — Managing incidental findings responsibly 17:34 — Connecting diagnostics to health economics 24:07 — Addressing disparities, access, and data bias 27:33 — Moving from research to routine clinical care 32:39 — Empowering patients through health technology Featured Topics Real-world evidence Personalized medicine Genomics and AI Diagnostic innovation At-home testing Reimbursement and payer coverage Health economics Data diversity and bias Patient engagement Clinical workflow integration Resources hc1 [https://hc1.com/] uMed [https://www.umed.io/about-us] Simple HealthKit [https://www.simplehealthkit.com/about] Closing Thought The next era of healthcare will not be defined by more testing alone. It will be defined by whether diagnostics can help turn real-world data into earlier action, better decisions, and measurable improvements in care.

The Hospital Room That Watches Over Patients (Without Replacing Nurses)

The hospital room is becoming intelligent. In this episode of Boombostic Health, Bradley Bostic sits down with Adam McMullin, CEO of AvaSure, to discuss how AI-enabled virtual care is helping health systems improve patient safety, support nurses, and extend clinical capacity without losing the human touch. AvaSure pioneered virtual safety and is now helping hospitals move beyond pilots into scalable, ROI-driven care transformation. Adam shares how intelligent room technology, computer vision, virtual nursing, and open platform integrations are changing what care teams can see, how quickly they can act, and where scarce clinical resources can be used most effectively. The conversation gets into the real pressures facing health systems today: patient falls, ED boarding, documentation burden, specialty access, workforce shortages, and the rising issue of violence against care teams. This is not a conversation about AI replacing clinicians. It is about using AI and virtual care infrastructure to give clinicians better visibility, better support, and more time with patients. Key Topics Virtual safety and the future of patient observation How intelligent rooms can reduce risk and improve workflow Why hard-dollar ROI matters for scaling healthcare technology The role of AI, computer vision, and virtual nursing in care delivery How AvaSure is helping health systems bring more human connection back into care Key Takeaway The future of hospital innovation is not more disconnected technology. It is intelligent infrastructure that helps care teams act sooner, work smarter, and care better.

AI Is Rewriting Diagnostics - Here's What's Coming Next

Transforming Diagnostics: Unlocking Value in the Future of Healthcare In this episode of Boombostic Health, Bradley Bostic sits down with Robert Michel, founder of Executive War College and editor-in-chief of The Dark Report, for a wide-ranging conversation on the past, present, and future of laboratory diagnostics. From the origin story behind Executive War College to the rise of genomics, AI, remote monitoring, and personalized medicine, Robert shares why diagnostics are far more than a line item in healthcare spending. They are one of the most powerful levers for improving outcomes, reducing cost, and helping health systems act earlier. The conversation explores how lab data can move from being underused information to a strategic asset that supports better decisions across maternal health, chronic disease, medication optimization, aging in place, and preventive care. In this episode Bradley and Robert discuss: * Why the name Executive War College reflects the strategic decisions lab leaders face * How genomics has evolved from early PCR testing to affordable whole-genome sequencing * Why diagnostics are central to early detection, patient monitoring, and better outcomes * How proactive lab-driven interventions can reduce avoidable healthcare costs * Why lab services are often viewed as a cost center despite their impact on total medical spend * How labs can become strategic partners by turning data into actionable insight * The role AI may play in faster, more precise diagnostic decision-making * How wearables, remote monitoring, robotics, and personalized health data could reshape care * Why nutrition, microbiome, lifestyle, and prevention are becoming harder to separate from healthcare * What longevity research and Blue Zones can teach us about healthspan * Why early adopters and innovation communities matter in advancing healthcare transformation Key takeaways Diagnostics are no longer just about test results. They are becoming a strategic intelligence layer for healthcare. Lab data has the potential to help health systems identify risk earlier, intervene sooner, and reduce avoidable cost. The future of healthcare will be shaped by the convergence of diagnostics, AI, remote monitoring, personalized medicine, and more proactive care models. Timestamps 00:00 — Why "Executive War College" became the name and what it signals about lab leadership 02:09 — The evolution of genomics technology since 1995 04:49 — From genetic research to practical diagnostic applications 06:14 — Unlocking the value of lab data for outcomes and cost savings 09:57 — How proactive lab testing can improve maternal and neonatal health 12:56 — Addressing anemia, medication optimization, and other preventable gaps 16:54 — The future of diagnostics, AI, and rapid medical insight 17:43 — Biometric wearables, holistic health, and extending healthspan 20:08 — Nutrition, microbiome, and the shift toward preventive care 25:38 — Lessons from Blue Zones on diet, longevity, and lifestyle 27:24 — Robotics, AI, and aging-in-place care models 32:02 — The future of pharmaceuticals, longevity, and space-age innovation 33:08 — Why innovation communities and early adopters drive progress

The Test That Could Catch Pancreatic Cancer Before It's Deadly

Are we really close to catching pancreatic cancer early? This silent killer still kills 75% within the first year of diagnosis. But what if we could spot clues before it becomes deadly? Transforming Pancreatic Cancer Detection with Amplified SciencesIn this episode, Bradley Bostic hosts Diana Caldwell, CEO and co-founder of Amplified Sciences, to explore groundbreaking advancements in early detection of pancreatic cancer. Given the devastating prognosis of late-stage diagnosis, their discussion highlights how innovative diagnostics can shift the paradigm towards earlier, less invasive screening—saving lives and improving outcomes.Main insights: * The dire statistics of pancreatic cancer survival rates highlight an urgent need for better screening. * Amplified Sciences has developed a multi-omics approach that detects precancerous cysts, much like colon polyps, allowing preemptive intervention. * The current standard, often reactive, diagnosis leads to late-stage detection; the new method aims to identify risks before symptoms appear. * They discuss the importance of high negative predictive value (NPV) to rule out malignancy non-invasively. * The platform uses minimal cyst fluid — only 10 times less than existing tests — crucial for small lesions. * The approach combines various biomarkers (proteomic, enzymatic, genetic) to improve accuracy. * Blood-based screening for early detection remains challenging, but amplification of fluid samples offers more precise insights. * Regulatory milestones, like CAP accreditation, position Amplified Sciences for wider clinical adoption. * Payer and coverage discussions are ongoing but vital for making this technology accessible. * The episode emphasizes how technological innovation, multidisciplinary collaboration, and early detection can revolutionize pancreatic cancer care. Timestamps: 00:11 - Introduction and personal story highlighting the importance of early cancer detection 01:08 - Diana Caldwell's background and motivation to improve gastroenterology diagnostics 04:38 - The science behind Amplified Sciences' diagnostic platform and research origins 07:27 - Current challenges in pancreatic cancer diagnosis and the limitations of standard tests 09:18 - Understanding the brutal statistics and silent progression of pancreatic cancer 10:12 - How genetic factors and incidental screening can identify high-risk individuals 12:41 - The patient journey: from incidental detection to invasive procedures and unmet needs 14:15 - The role of the PANSIS Pro test, regulatory milestones, and sample requirements 16:03 - Differentiating between benign cysts and pre-malignant lesions like IPMN 17:24 - The significance of multi-omic diagnostics and reducing unnecessary surgeries 21:18 - Screening strategies: incidentally detected lesions and the importance of size and location 24:04 - Limitations of current biomarkers like CA 19-9 and the promise of multi-marker panels 26:02 - The unique approach of liquid-focused diagnostics versus traditional blood tests 29:18 - Reimbursement hurdles and the importance of demonstrating clinical utility 32:13 - The mental health impact of uncertain diagnoses and proactive testing benefits 33:55 - The vision for a future where early detection becomes routine and standard careResources & Links: Resources & Links: Amplified Sciences Official Website: https://amplifiedsciences.com/ [https://amplifiedsciences.com/] Connect with Diana Caldwell on LinkedIn: https://www.linkedin.com/in/dianathompsoncaldwell/ This episode underscores the power of innovative diagnostics to intercept pancreatic cancer early, transforming a deadly prognosis into manageable health outcomes. It highlights the collaborative effort needed across research, regulation, and healthcare platforms to ensure these breakthroughs reach patients.